8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 27, 2009)

Filed April 27, 2009For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on April 27, 2009, to report its financial results for the first quarter of 2009. The company issued a press release detailing these results, which included information on its operations and financial condition. A significant portion of the press release is considered 'filed' with the SEC under the Exchange Act, indicating its importance for investor review. The filing primarily serves to disseminate the company's first-quarter performance. Investors should examine the accompanying press release (Exhibit 99.1) for specific financial metrics, sales figures, profitability, and any forward-looking statements or guidance provided by management regarding the outlook for the rest of the year. The Chief Financial Officer, Thomas M. Abate, signed off on the filing, underscoring the official nature of the disclosed financial information.

Key Highlights

  • 1Edwards Lifesciences (EW) reported its Q1 2009 financial results via an 8-K filing.
  • 2The filing includes a press release (Exhibit 99.1) with detailed financial information.
  • 3Certain sections of the press release are deemed 'filed' with the SEC, making them subject to reporting requirements.
  • 4The report focuses on the company's results of operations and financial condition for the first quarter.
  • 5Thomas M. Abate, Corporate Vice President, Chief Financial Officer and Treasurer, signed the filing.
  • 6Investors are directed to the press release for specific financial performance data and management commentary.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report and disseminate Edwards Lifesciences' financial results for the first quarter of 2009 to investors and the public through an accompanying press release.

The specific financial details are located within the press release filed as Exhibit 99.1 to this 8-K. Certain sections of this press release are considered 'filed' for SEC purposes.

When a portion of a press release is deemed 'filed' with the SEC, it means that the information contained within those specific sections is subject to the same legal liabilities and reporting requirements as other formal SEC filings, such as the annual 10-K or quarterly 10-Q reports.

Thomas M. Abate is the Corporate Vice President, Chief Financial Officer, and Treasurer of Edwards Lifesciences. His signature on the 8-K filing signifies that the company's management has reviewed and authorized the disclosed financial information.